Interim analysis of a phase 3 trial in 734 previously vaccinated Japanese adults: S-268024 booster was non-inferior and superior to NVX-CoV2373 for day-29 neutralising antibody titres (GMT ratio 1.79), with more treatment-related adverse events (92.4% vs 77.5%).
RCTn = 734
Nakano et al. Immunogenicity and safety of a SARS-CoV-2 recombinant vaccine S-268024 booster vaccination versus NVX-CoV2373: Interim results from a phase 3, multicenter, randomized, observer-blind, active-controlled study